Sierra Summit Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.6% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,575 shares of the company's stock after acquiring an additional 719 shares during the quarter. Eli Lilly and Company makes up 2.1% of Sierra Summit Advisors LLC's holdings, making the stock its 15th largest holding. Sierra Summit Advisors LLC's holdings in Eli Lilly and Company were worth $9,560,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the business. PNC Financial Services Group Inc. boosted its stake in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after purchasing an additional 50,002,551 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after buying an additional 14,852,076 shares during the period. Vanguard Group Inc. boosted its position in Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after acquiring an additional 4,975,395 shares in the last quarter. Capital International Investors increased its holdings in shares of Eli Lilly and Company by 23.2% in the 4th quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after acquiring an additional 1,645,222 shares during the period. Finally, Capital Research Global Investors raised its position in shares of Eli Lilly and Company by 16.1% in the 4th quarter. Capital Research Global Investors now owns 10,757,511 shares of the company's stock worth $8,304,811,000 after acquiring an additional 1,493,673 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on LLY shares. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price objective for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Guggenheim lifted their price target on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a report on Friday, July 11th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average target price of $990.89.
Check Out Our Latest Research Report on Eli Lilly and Company
Eli Lilly and Company Price Performance
Shares of NYSE:LLY opened at $625.15 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company's 50 day moving average is $774.10 and its 200 day moving average is $798.80. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $972.53. The company has a market cap of $592.48 billion, a PE ratio of 40.86, a price-to-earnings-growth ratio of 0.91 and a beta of 0.44.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 98.25%. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the previous year, the company earned $3.92 earnings per share. The firm's revenue for the quarter was up 37.6% on a year-over-year basis. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.
Eli Lilly and Company Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 1.0%. Eli Lilly and Company's payout ratio is currently 48.82%.
Insider Activity
In other news, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.
Eli Lilly and Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
